Kahimmune Secures Exclusive Kahinomics Rights to Power Shared mRNA Vaccines
Kahimmune Therapeutics has signed an exclusive licensing agreement with Gustave Roussy and Société d’Accélération du Transfert de Technologies (SATT) Paris-Saclay, securing the intellectual property behind its Kahinomics platform and the tumour neoantigens it generates, branded as “Kahigens”.
In plain terms: the company has locked in the rights to a discovery engine – and the first wave of targets that come out of it – so it can move from intriguing science to real-world product development.
Kahimmune, created at the end of 2025, is building on a fast-emerging area of immunology: the so-called “dark genome”, referring to stretches of genetic material outside the classic protein-coding regions that have historically dominated drug discovery.
Kahinomics is designed to identify tumour-specific antigens in those overlooked regions, potentially expanding the menu of “flags” the immune system can be trained to recognise as cancer.
The ambition is to translate those Kahigens into shared messenger RNA (mRNA) cancer vaccines – “shared” meaning not bespoke for just one person, but engineered around antigen targets that could apply across groups of patients.
Kahimmune’s strategy is also built around combination use: vaccines that are optimised to be administered alongside other cancer treatments, with the aim of improving not just survival, but quality of life too – an important distinction in aggressive disease areas where the burden of treatment can be as defining as the illness itself.
Its first vaccine candidate is planned for colorectal cancer and pancreatic cancer – two indications where clinical need is high and, in many settings, outcomes remain stubbornly difficult to shift.
World Health Organization describes colorectal cancer as the third most common cancer worldwide and the second leading cause of cancer-related deaths globally. Pancreatic cancer is less common by incidence, but disproportionately lethal; the WHO’s cancer agency notes it as one of the leading causes of cancer death, and among the least favourable prognoses.
Company leadership is framing the licensing deal as more than paperwork. The Founder and CEO said Kahimmune is going after cancers that are “extremely common, aggressive and fast growing”, and that the exclusive transfer agreement gives the start-up solid R&D assets and a meaningful competitive edge as it enters the cancer vaccine arena.
From the technology-transfer side, SATT Paris-Saclay’s Life Sciences Investments director described the work as addressing a major clinical need – and positioned the creation of Kahimmune as a crucial step towards pushing the innovation closer to patients.
Conclusion
By securing exclusive rights to Kahinomics and its Kahigen neoantigens, Kahimmune is betting that the “dark genome” can reveal new, actionable targets for immuno-oncology – and that those targets can be packaged into shared mRNA vaccines designed to work alongside existing cancer therapies.
With an initial focus on colorectal and pancreatic cancers, the company is squarely aiming at high-burden disease areas where better immune-guided options could make a real difference in both outcomes and day-to-day patient experience.
News Credits: Kahimmune Therapeutics enters licensing agreement with Gustave Roussy and SATT Paris-Saclay
Things you may also like:
- Twinings Adds a Peach Twist to Its Sparkling Tea Push
- CERo Flags Early Safety Signals for CER-1236 in First-in-Human AML Study
- ErVimmune Secures €17m to Push Cancer Vaccine Towards First-in-Human Trial